PATRICK G. LEPORE - 30 Nov 2021 Form 4 Insider Report for VYNE Therapeutics Inc. (VYNE)

Role: Director
Signature: /s/ Mutya Harsch, attorney-in-fact for Patrick LePore
Issuer symbol: VYNE
Transactions as of: 30 Nov 2021
Net transactions value: +$12,699
Form type: 4
Filing time: 02 Dec 2021, 16:08:05 UTC
Previous filing: 30 Nov 2021
Next filing: 10 Feb 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	VYNE	Common Stock	Purchase	$12,699	+12,500	+25%	$1.02	62,500	30 Nov 2021	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Shares were purchased pursuant to a 10b5-1 plan entered into by the reporting person on April 21, 2021.
F2	The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $0.98 to $1.03, inclusive. The reporting person undertakes to provide to VYNE Therapeutics Inc., any security holder of VYNE Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

Content

Shares were purchased pursuant to a 10b5-1 plan entered into by the reporting person on April 21, 2021.

The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $0.98 to $1.03, inclusive. The reporting person undertakes to provide to VYNE Therapeutics Inc., any security holder of VYNE Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.